Clinical trial · Interventional
Efficacy of Dihydroartemisinin for Treating PCOS
Therapeutic Efficacy of Dihydroartemisinin in Patients With Polycystic Ovary Syndrome
NCT06417099CI-TRIAL-00088811completedPhase 2ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The primary research hypothesis of this study is that dihydroartemisinin is effective in restoration of regular menstrual cycles of PCOS subjects who meet at least two of three Rotterdam Criteria. Secondary research hypotheses include: dihydroartemisinin is also effective in reducing androgen, total immature follicles, and anti-Mullerian hormone.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Polycystic Ovary Syndrome | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Dihydroartemisinin | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- Dihydroartemisinin Treatment Arm
- description
- The subjects take dihydroartemisinin, 40mg tid for 90 days
- interventionNames
- Drug: Dihydroartemisinin
Primary outcomes (1)
- measure
- Recovery of regular menses
- timeFrame
- 180 days
- description
- Record of vaginal bleeding within 6 months after start taking dihydroartemisinin
Secondary outcomes (3)
- measure
- Serum anti-Mullerian hormone (AMH)
- timeFrame
- 90 days
- description
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 18 Years
- Maximum age
- 40 Years
Show eligibility criteria text
Inclusion Criteria: * BMI 18.5-28kg/M2 * No plan for pregnancy in the coming 6 months * Patients should meet two of the three following criteria: 1. Irregular cycles and ovulatory dysfunction: \< 21 or \> 35 days or \< 8 cycles per year; \> 90 days for any one cycle 2. Polycystic ovaries: ≥12 follicles in at least one of two ovaries (diameter\<10mm), confirmed by ultrasound. 3. Elevated androgen levels: total testosterone\>1.67 nmol/L. Exclusion Criteria: * Pregnancy. * Patients with other endocrine diseases that can cause secondary PCOS, including but not limited to: 21 hydroxylase deficiency, prolactinoma, hypothyroidism, Cushing's syndrome, etc. * Patients with other serious diseases affecting heart, liver, kidney, or other major organs. * Patients with any type of cancer.
References
Publications (0)
Data not yet available
No reference posted for this study.